

The Actuarial Profession
making financial sense of the future

Pensions & Corporate Finance Seminar
Peter Elwin



Implications of How Analysts Assess Pension Risk

What do equity and credit analysts want to know?

Key questions

- What's the liability?
- What cash might the company have to pay out and when?
- What risks is the company exposed to as a result of the Scheme?

UK-specific issues



- Funded schemes are more complicated than unfunded ones
- The UK regulatory regime creates additional risks for investors

The assets appear easy to understand

- Annual report discloses mix and values
- Supercharged beta?
 - Falling equity markets drive down fund values
 - Deficit grows, driving down the value of the company
- This creates a negative feedback loop...
 - But it works the other way in a rising market
- LDI structures, longevity swaps, etc are harder to understand (disclosure is poor)

The liability is much more difficult

- BT pension - total (undiscounted) cash flows (est): c. £128bn
- 90 year run off
- But discount rate volatility (AA spread) in 2008/9 has made IAS 19 liabilities swing wildly (>25%)



So what do credit and equity analysts do? (Unrewarded complexity)

- Use the (last reported) IAS 19 balance sheet figures
 - Deduct IAS 19 deficits, ignore surpluses
- Credit analysts adjust the P&L or use cash flow figures
- Equity analysts don't always question the P&L
 - Equity risk may be rewarded in earnings-based valuations
- Known unknowns:
 - No disclosure of cashflows, actuarial funding, or buyout liabilities
 - New cash demands are hard to predict
- Funding announcements and contributions agreements matter

What's the result?

- Credit ratings are affected by pension deficits and funding agreements
- Share price reaction is inconsistent - sometimes pensions matter, and sometimes they don't!
 - Asset value changes are expected, liabilities tend to surprise
- Buyout liabilities - the Elephant in the M&A data room
 - Private equity firms, hedge funds and insurance companies take a very different view
- Trustees are an unknown quantity
- Pension deals (buyouts, buy-ins, longevity swaps, contingent assets, etc) are hard for the markets to value

Implications for 2010

- Y/e 09/10 IAS 19 figures - equity beta beaten by other Greeks
- 2009 funding reviews will be ugly
 - Trustees will continue to de-risk their investments
 - The focus on sponsor covenants will increase
- Companies want to reduce pension risk
 - More CFOs will hard-close schemes
 - Longevity swaps = being seen to do something (cheaply)
 - Buy-ins - expect a resurgence
 - Buyouts - will probably remain rare
- M&A will renew the focus on trustees, funding, and tPR powers

Longer term trends

- Equity allocation will continue to reduce (towards 40%?)
- Lack of bonds will force investors to look for alternatives
- Fear of inflation + supply squeeze = cap on rising real yields
- Pension inequalities will create significant HR and political issues
 - Private sector: majority (underfunded) DC vs minority DB
 - Public sector (unfunded) DB

Disclaimer

This report has been prepared for information purposes only and is not a solicitation, or an offer, to buy or sell any security or to participate in any trading strategy. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The information on which the report is based has been obtained from sources which we believe to be reliable, but we have not independently verified such information and we do not warrant that it is accurate or complete. All expressions of opinion are subject to change without notice. Third party data providers make no warranty relating to the accuracy, completeness or timeliness of their data and shall have no liability whatsoever for losses that may arise from reliance upon such data. J.P. Morgan Cazenove Limited shall have no liability whatsoever for losses that may arise from reliance upon this report (including, without limitation, such third party data). This report is confidential and for your internal business purposes only. This report is solely for institutional investors to whom it is addressed and must not be disclosed to or relied upon by any other institutional or non-institutional investor for any purpose whatsoever. This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial objectives and circumstances of the recipients. You should consider this report as only a single factor in making an investment decision. J.P. Morgan Cazenove Limited and its connected companies, and their respective directors, officers and employees may from time to time have a long or short position, or other interest, in the securities mentioned and may sell or buy such securities and may trade them in ways different from those discussed or recommended in this report.

Additional information with respect to any securities referred to herein will be available upon request.

Note to recipients in Australia: J.P. Morgan Cazenove Limited is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 in respect of its brokerage and research services. J.P. Morgan Cazenove Limited is regulated under UK laws, which differ from Australian laws.

THIS RESEARCH HAS BEEN PRODUCED BY J.P. MORGAN CAZENOVE LIMITED IN LONDON. IT HAS NOT BEEN PRODUCED IN THE UNITED STATES OR BY CAZENOVE INC. Proposed transactions by U.S. persons in the securities described in this report should be discussed with Cazenove Inc. and not J.P. Morgan Cazenove Limited.
©2010 J.P. Morgan Cazenove Limited.

The registered address of J.P. Morgan Cazenove Limited is 20 Moorgate, London EC2R 6DA
Telephone +44 (0)20 7155 5000 Facsimile +44 (0)20 7155 5900
Research web site: <http://www.cazenoventools.com>
J.P. Morgan Cazenove Limited is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.
